According to the results of ER, PR, HER2, Ki-67, CK5/6, and EGFR staining, 49 cases (35.8%) were classified as luminal A, 48 (36.9%) were luminal B-HER2 (-), 23 (17.7%) were luminal B-HER2 (+) [19 (14.6%) were luminal B-HER2 PR (+), four (3.1%) were luminal B-HER2 PR (-)], four (3.1%) were HER2-enriched, and six (4.4%) were triple-negative breast carcinoma. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.